CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness

Last updated: April 19, 2017
Project Number: RB1085-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness the use of fondaparinux to treat patients with type II heparin-induced thrombocytopenia?
  2. What is the clinical effectiveness the use of direct oral anticoagulants to treat patients with type II heparin-induced thrombocytopenia?

Key Message

One systematic review and eight non-randomized studies were identified regarding the clinical effectiveness of fondaparinux and/or direct oral anticoagulants to treat patients with type II heparin-induced thrombocytopenia.